Loading...
Loading...
OABI| Name | Value |
|---|---|
| Revenues | 4.2M |
| Cost of Revenue | 0.0M |
| Gross Profit | 4.2M |
| Operating Expense | 23.9M |
| Operating I/L | -19.8M |
| Other Income/Expense | 0.7M |
| Interest Income | 0.7M |
| Pretax | -19.1M |
| Income Tax Expense | -2.7M |
| Net Income/Loss | -16.4M |
OmniAb, Inc. is a biotechnology company that offers therapeutic antibody discovery technologies in the United States. The company's OmniAb platform utilizes genetically modified transgenic animals, such as OmniRat, OmniChicken, and OmniMouse, to produce antibodies with human sequences, enabling the development of human therapeutic candidates. Additionally, OmniFlic and OmniClic cater to the industry's demand for bispecific antibody applications through a common light chain approach. OmniTaur provides unique structural attributes of cow antibodies for complex targets. OmniAb generates revenue by providing industry partners access to its diverse antibody repertoires and screening technologies, facilitating the discovery of next-generation therapeutics.
